- Published
- Updated
- Sources checked
A bioavailability or bioequivalence study can lose interpretability through a small handoff failure. Readiness must connect controlled dosing and sample timing with the laboratory's actual processing and analysis workflow.
Confirm the study-specific route
TİTCK publishes specific ethics committee arrangements for BA/BE studies and general application requirements. Confirm the applicable route and study design rather than borrowing a therapeutic trial start-up checklist unchanged. Clinical conduct and analytical readiness both need study-specific evidence before the planned dosing session.
Map dosing to analytical evidence
We recommend a timed rehearsal from participant check-in through dose administration, blood collection, processing, freezing and courier handover. Record clock synchronization, backup equipment and who resolves a missed sample. Use the protocol's sampling windows; do not invent a universal tolerance from another study or assay.
Check a timed rehearsal
- Reconcile product identity, batch information, dosing instructions and accountability records.
- Check eligibility, consent and emergency arrangements for the planned participant group.
- Verify sample labels, collection times, processing instructions and storage capacity together.
- Confirm laboratory receipt criteria, shipment evidence and handling of timing exceptions.
Protect traceability through transfer
Agree how actual times and sample condition reach the analytical team without rewriting source records. Keep the clinical and laboratory exception logs linked. A validated analytical method cannot compensate for an untraceable sample or a poorly documented dosing event.
Frequently asked questions
- Can a standard therapeutic trial checklist cover BA/BE?
- It may contribute, but timed dosing, sampling and analytical interfaces require dedicated controls.
- Should missed sampling times be rounded?
- Record actual times and assess the deviation using the protocol and analysis plan.